MamoRisk provides the equivalent of \u201ca calculator into which each woman\u2019s risk factors are entered, producing a classification of low, intermediate or high risk over a two- and five-year period,\u201d the research team explains. The project is led by the Santiago de Compostela Health Research Institute (IDIS), the Spanish National Cancer Research Centre (CNIO) and the Galicia Sur Health Research Institute (IISGS).\u00a0<\/p>\n
Spain\u2019s Ministry of Science, Innovation and Universities (MICIU) is funding MamoRisk with \u20ac1.2 million from the European NextGenerationEU programme, through the Precision Personalised Medicine call for proposals launched by the Carlos III Health Institute (ISCIII). The ministry\u2019s involvement extends beyond funding, since two of the organisations conducting the study are linked to the Carlos III Health Institute: CNIO is a foundation affiliated with the ISCIII, while IDIS is one of the 36 Health Research Institutes accredited by the ISCIII throughout Spain.\u00a0<\/p>\n
MamoRisk has just begun in Galicia. During this initial phase, women diagnosed with breast cancer and healthy women have started receiving invitations to participate in the study. In addition to Galicia, the autonomous communities participating in MamoRisk are Madrid, Cantabria, Castilla-La Mancha, Murcia, Extremadura, Asturias, Castilla y Le\u00f3n, Andalusia, Arag\u00f3n, Catalonia, La Rioja, the Valencian Community and the Canary Islands.\u00a0<\/p>\n
A total of 4,000 women diagnosed with breast cancer and 6,000 healthy women will be invited to participate. They will be randomly selected from women who have been monitored for at least six years through the early-detection programmes of the 14 autonomous communities. The model will be applied using their clinical and epidemiological data and genetic information obtained from a saliva sample. Its predictions will then be compared with what actually occurred during the follow-up period.\u00a0<\/p>\n
Should the risk-prediction model prove effective and begin to be used in screening programmes, women with a higher probability of developing cancer could be offered much more intensive monitoring. The aim is to detect cancer earlier or, where possible, introduce targeted preventive measures.\u00a0<\/p>\n